Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - IntelGenx Corp. (IGXT.OB-OTC: BB) |
|
|
“Our focus is on oral drug delivery. Our platform technologies include systems for controlled release and immediate release dosage forms. Our controlled-release technology is based on layered tablets that consist of a non-erodible layer containing the active drug and one or more erodible cover layers. Upon contact of the tablet with the gastro-intestinal fluid, the cover layers erode at a pre-determined rate. This “controlled erosion” controls the release of an active drug from the...” - Horst G. Zerbe, Ph.D. (IGXT) (Interview published July 25, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
IntelGenx Corp. and Cary
Pharmaceuticals Inc. Announce Successful End-of-Phase II Meeting
With FDA for Development of Their Antidepressant CPI-300
Wednesday July 30, 8:17 am ET
SAINT LAURENT, QUEBEC and GREAT FALLS, VIRGINIA--(MARKET
WIRE)--Jul 30, 2008 -- IntelGenx Corp. (CDNX:IGX.V
- News)(OTC
BB:IGXT.OB -
News) ("IntelGenx"
or the "Company") and Cary Pharmaceuticals Inc. ("Cary Pharma")
today announced that the companies recently met with the U.S.
Food and Drug Administration (FDA) in an End-of-Phase II meeting
for its antidepressant, CPI-300 at which the FDA indicated that
it will accept a recently completed pivotal food effect study as
sufficient to support a 505(b)(2) NDA submission. After
reviewing the study results, the FDA confirmed that it will
accept a labeling that the product may be taken without regard
to food. With respect to the remaining clinical program, the FDA
confirmed that it will require a single-dose, fasting, two-way
crossover study vs. the Reference Listed Drug (RLD) to support
the 505(b)(2) NDA submission. The companies anticipate that the
remaining clinical development will be completed in Q3, 2008 and
plan to submit the 505(b)(2) NDA in Q4, 2008.
"The End-of-Phase II meeting with FDA is very important to the
development program for CPI-300. During this meeting, the FDA
provided clarification about the clinical trials and stability
studies required to support a 505(b)(2) NDA. We are excited that
FDA has provided a clear direction for our CPI-300 development
program and our clinical plans. The completion of the pivotal
food effect study and its acceptance by the FDA is a critical
milestone in our development program. We are now moving full
speed ahead to complete the remaining clinical development and
stability testing in Q3 2008 with the submission of a 505(b)(2)
NDA in Q4 2008," said Dr. Horst Zerbe, CEO of IntelGenx.
"We are pleased to be partnering with IntelGenx on this important program. The clinical and stability results achieved for CPI-300 are very encouraging. These results provide further confidence that our development team will be able to complete product development in a timely manner," said Douglas D. Cary, President and CEO of Cary Pharmaceuticals. ABOUT INTELGENX CORP. IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain management, hypertension, osteoarthritis, and depressive disorders. About CARY PHARMACEUTICALS INC. Cary Pharmaceuticals Inc. is a specialty pharmaceutical company located in Northern Virginia. The company's product pipeline includes CPI-300 for the treatment of depression, QuitPak® for smoking cessation, and Tempol for the treatment of hypertension. FORWARD LOOKING STATEMENTS This news release contains certain forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding potential product development and trial results, and the future plans and objectives of IntelGenx are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from IntelGenx 's expectations are disclosed elsewhere in documents that are available to the public at www.sec.gov.
Contact: Contacts: IntelGenx Corp. Dr. Horst G. Zerbe President and CEO 514-331-7440 (ext. 201) 514-331-0436 (FAX) horst@IntelGenx.com http://www.intelgenx.com Cary Pharmaceuticals Inc. Douglas D. Cary President and CEO 703-759-7460 info@carypharma.com http://www.carypharma.com Source: IntelGenx Corp.
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.